This study presents a novel approach utilizing the concentration gradient of thiourea dissociation products to synthesize a ...

After the disappointing result, BioMS, the Edmonton, Alberta–based startup behind the trial, abandoned development of the vaccine. Meanwhile, the industry remains without a targeted therapeutic ...